LDS/Medical Tests/Benzodiazepines, Confirmation, Urine

Benzodiazepines, Confirmation, Urine

The Benzodiazepines are a class of medications (drugs) that may produce the following effects: sedation, anticonvulsant, hypnotic, muscle relaxation, relief of anxiety, and relief of nausea. All are characterized by the fusion of a benzene ring to a seven-membered diazepine ring that contains a phenyl ring attached to the 5-position of the diazepine ring. They are one of the most widely prescribed drugs in the Western hemisphere because of their efficacy, low addiction potential, safety, and minimal side effects when taken as prescribed.  Due to these features, benzodiazepines have replaced the use of barbiturates as the major class of CNS-depressants. Benzodiazepines exert their effects by enhancing the response of the receptor for the neurotransmitter GABAA in the CNS by opening chloride channels resulting in hyperpolarization and diminished neural electrical discharge, which makes the neuron more resistant to excitation.  

The most common benzodiazepines are the prescription drugs diazepam (Valium), alprazolam (Xanax), triazolam (Halcion), lorazepam (Ativan), and clonazepam (Klonopin). As with barbiturates, the benzodiazepines are categorized as short-acting, medium-acting, and longer acting drugs. Short-acting benzodiazepines are generally used for sedation and amnesia while the longer-acting variants are used to treat anxiety. Some benzodiazepines can be used as anticonvulsants, such as clonazepam, diazepam, and clorazepate.

Benzodiazepines are a controlled substance as schedule IV of the Controlled Substance Act. Benzodiazepines are a class of drugs that are commonly used by drug abusers, in particular heroin and cocaine using populations. Long-term abuse can lead to respiratory depression or, in severe cases, coma. Alprazolam and diazepam are the two most frequently encountered benzodiazepines on the illicit market today.

Benzodiazepines undergo hepatic oxidation (phase I) and conjugation (phase II).  This results in metabolites that may retain pharmacologic activity.  Cytochrome p450 enzymes, in particular the variants CYP3A4 and CYP2C19, are commonly involved in metabolism. Drugs and other substances that inhibit CYP3A4 (e.g. erythromycin, ketoconazole, and grapefruit juice) can affect the metabolism of various benzodiazepines.   Benzodiazepines tend to be excreted into the urine, allowing detection by various methods including screening tests using immunoassay and confirmatory tests utilizing gas chromatography coupled with mass spectroscopy, and liquid chromatography coupled with mass spectroscopy.

Benzodiazepines can elicit the following paradoxical effects: hostility, irritability, and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death. They cross into the placenta and are present in breast milk. About 80% of serum drug is bound to albumin. Elevated concentrations can occur in elderly and those with severe liver disease.

  • Drug abuse evaluation; patient use of non-prescribed benzodiazepines
  • Toxicity assessment in serum; although serum concentrations are not predictive of severity of intoxication
  • Patient Compliance with prescribed benzodiazepines
A qualitative positive result from an immunoassay (IA) screening test indicates only the presence of any one of the drugs in the benzodiazepine class and is not specific for any particular drug.  Due to the variety of immunoreactivities among active drug and metabolites, immunoassays will rarely detect all members of the benzodiazepine class. Quantitative results can be obtained utilizing gas chromatography (GC) or liquid chromatography (LC) coupled with mass spectroscopy (MS), and does not necessarily correlate with the extent of physiological and psychological effects. Any positive screening result should be confirmed by a non-immunological quantitative method such as GC, LC/MS or GC/MS.

Negative (less than cutoff).

Therapeutic concentration: Varies by benzodiazepine drug.

Toxic concentration: Varies by benzodiazepine drug.

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-Off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as immunoassay, or a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Immunoassay, Liquid Chromatography/Mass Spectroscopy (LC/MS), Gas Chromatography/Mass Spectroscopy (GC/MS). The main method of quantification is via LC/MS. This particular method of analysis is used to not only detect the parent drug compound, but may also detect the major metabolites of the particular benzodiazepine in question. Active metabolites should be quantified to assess the overall concentration of the particular benzodiazepine in question. Benzodiazepines can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis, since some benzodiazepines are unstable in acid medium and rearrange to form benzophenones.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability (analyte dependent):

  • Ambient: up to 7 days
  • Refrigeration: up to 14 days
  • Frozen: 180 days
Pain drug management pharmacogenomics panel or CYP3A4, CYP2C19 may be tested for drug safety and efficacy before prescribing. Supportive testing such as Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC (if overdose), other drugs if necessary.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
  • Ann Clin Biochem. 1997 Sep;34 (Pt 5):460-510. [PMID: 9293303]
  • Cochrane Database Syst Rev. 2012 Jul 11;7:CD007139. [PMID: 22786504]
  • Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
  • Principles of Forensic Toxicology, Fourth Edition. Barry Levine (Ed.). AACC Press, Washington DC, Chapter 14, Benzodiazepines, pp. 237-251 (2013).
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds.). Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
  • Baselt RC (ed.). Disposition of Tox Drugs and Chemicals in Man, Sixth Edition, Biomedical Publications, Foster City, CA (2002).
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79.
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology 1989;11(4): 7-20.